PT  - JOURNAL ARTICLE
AU  - V M Martínez-Taboada
AU  - V Rodríguez-Valverde
AU  - L Carreño
AU  - J López-Longo
AU  - M Figueroa
AU  - J Belzunegui
AU  - E M Mola
AU  - G Bonilla
TI  - A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects
AID  - 10.1136/ard.2007.082115
DP  - 2008 May 01
TA  - Annals of the Rheumatic Diseases
PG  - 625--630
VI  - 67
IP  - 5
4099  - http://ard.bmj.com/content/67/5/625.short
4100  - http://ard.bmj.com/content/67/5/625.full
SO  - Ann Rheum Dis2008 May 01; 67
AB  - Objective: Open label studies have suggested that tumour necrosis factor (TNF) antagonists led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA). To confirm these observations, we conducted a randomised, double-blind, placebo controlled trial with etanercept in patients with biopsy-proven GCA with side effects secondary to corticosteroids.Methods: We randomly assigned patients with GCA to receive etanercept (n = 8) or placebo (n = 9) over 1 year together with corticosteroids that were reduced according to a predefined schedule. The primary outcome was the ability to withdraw the corticosteroid therapy and control the disease activity at 12 months.Results: Baseline characteristics were similar in the two groups, although patients in the etanercept group showed higher levels of basal glycaemia (p = 0.02) and a higher erythrocyte sedimentation rate (ESR) (p = 0.01). After 12 months, 50% of the patients in the etanercept group and 22.2% in the placebo group were able to control the disease without corticosteroid therapy (p value not significant). Patients in the etanercept group had a significant lower dose of accumulated prednisone during the first year of treatment (p = 0.03). There were no differences in the number and type of adverse events.Conclusion: The limited number of patients included in this study does not allow us to draw definitive conclusions. Etanercept therapy was well tolerated in this aged population. The therapeutic role of etanercept in patients with GCA should be evaluated in studies with a larger number of patients.